Karl Stonecipher, MD

They evaluate key efficacy data and patient outcomes from the COMET-2 and COMET-3 clinical trials.

The team reviews acoltremon’s mechanism in promoting basal tear production and maintaining ocular surface health.

Panelists discuss new DED treatments like Miebo and Vevye and how they integrate into treatment algorithms.

Experts highlight management nuances in patients with neuropathic pain, post–refractive surgery complications, or contact lens intolerance.

The panel addresses common patient frustrations and therapeutic limitations in today’s dry eye landscape.

Panelists share how they tailor therapy based on patient characteristics, symptoms, and clinical findings.

The discussion explores how basal and reflex tears differ and why composition impacts sustained eye comfort.

Experts explain how differentiating these subtypes guides treatment choices and outcomes.

Donaldson introduces the panel and outlines the series’ focus on improving dry eye management through tear function optimization.

Donaldson introduces the panel and outlines the series’ focus on improving dry eye management through tear function optimization.

Outcomes from high myopia LASIK using the Teneo laser platform demonstrate strong visual stability and patient satisfaction, with reduced dysphotopsias and minimal reliance on cycloplegia or nomograms.

Ophthalmologists end their discussion on the management of dry eye disease with other ocular comorbidities highlighting key takeaways and prospective advances in care and outcomes.

Experts offer clinical advice and when to refer patients to specialists and the importance of building a supportive care network for patients.

Ophthalmologists offer their clinical insights and best practices of procedural therapies for dry eye management prior to surgery.

Experts discuss how dry eye disease can impact the preparation and post-operative care of cataract or refractory surgery, highlighting key approaches to successfully managing these patients.

Ophthalmologists provide an overview of current anti-inflammatory agents available for dry eye disease and how they utilize these therapies for particular patient populations.

Experts discuss their experience managing patients with dry eye disease and glaucoma, highlighting how dry eye disease impacts the progression of glaucoma and key considerations for treatment.

Ophthalmologists provide insights into their diagnostic protocols for assessing dry eye.

Expert panelists discuss the co-occurrence of dry eye disease with other ocular comorbidities and highlight the frequently observed concurrent ocular conditions.